000950 重药控股
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入60,273,451-3.12%82,447,40980,561,53278,397,35467,829,010
减:营业总成本59,386,853-2.83%81,307,11579,839,41277,352,03866,608,402
    其中:营业成本56,159,847-2.71%76,507,07374,572,95872,130,85162,008,780
               财务费用485,589-12.96%738,0821,084,2811,302,0281,094,235
               资产减值损失(34,475)73.55%(123,168)(89,975)(27,756)(39,943)
公允价值变动收益(44)-94.93%(3,068)6,91916,1622,318
投资收益253,10080.80%415,481402,412301,548293,349
    其中:对联营企业和合营企业的投资收益219,898-2.03%479,395396,688291,454286,195
营业利润558,472-16.04%682,871562,641964,8831,435,011
利润总额557,224-15.24%671,860557,508966,3291,472,490
减:所得税费用152,02521.56%150,531155,717236,042309,496
净利润405,198-23.89%521,328401,791730,2881,162,995
减:非控股权益84,665-42.94%134,613118,798105,654210,719
股东净利润320,533-16.53%386,715282,994624,633952,276

市场价值指针
每股收益 (元) *0.186-16.52%0.2200.1600.3600.550
每股派息 (元) *----0.0600.0600.0500.060
每股净资产 (元) *6.8933.08%6.6756.5546.5076.110
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容